FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Beneath the surface of the tiny, see-through worm Caenorhabditis elegans, researchers have found new clues about how certain ...

A new discovery could pave the way for more effective cancer treatment by helping certain drugs work better inside the body.

Scientists have found a surprising new way to make certain cancer drugs work dramatically better – by helping them get inside ...

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy ...

Our brain's remarkable ability to form and store memories has long fascinated scientists, yet most of the microscopic mechanisms behind memory and learning processes remain a mystery.

Recent research sheds light on how changes in the chemical structure of a protein called Interleukin-6 affect lung cancer’s ...

Complex protein interactions at synapses are essential for memory formation in our brains, but the mechanisms behind these ...

Momentum Therapeutics Inc. has described receptor-interacting serine/threonine-protein kinase 3 (RIPK3) inhibitors reported to be useful for the treatment of systematic inflammatory response syndrome, ...

More insight into the process could improve crop productivity WEST LAFAYETTE, Ind. — Purdue University scientists have discovered a key mechanism that regulates how plants develop chloroplasts, ...

HepaRegeniX is backed by experienced life science investors, including Vesalius Biocapital IV, Novo Holdings A/S, Boehringer Ingelheim Venture Fund (BIVF), Coparion, High-Tech Gründerfonds, Ascenion ...

Following a recent Type D meeting with the FDA, a phase 3 clinical trial design for darovasertib in primary uveal melanoma ...